Leadership

Greg Loewen , Drug Transport

Greg Loewen graduated with a B.S. in Chemistry from Montana Tech in 1995 and performed natural products research for several years before joining XenoTech in 2000. From 2000 to 2005, Greg served as a Research Scientist and Study Director for GLP-compliant reaction phenotyping studies. In 2005, Greg focused his efforts in the analytical sciences group overseeing the development, validation and utilization of LC/MS methods in support of CYP enzyme inhibition, CYP enzyme induction and reaction phenotyping studies. In 2007 Greg accepted his current position of Senior Scientist in the Drug Transporter Department at XenoTech, overseeing drug transport studies and working with SOLVO Biotechnology and Sekisui Medical to promote their unique products and services in North America. Greg is an author or coauthor on several scientific posters and research publications.

Maciej Czerwinski , Ph.D.

Maciej Czerwinski is an Executive Research Consultant at XenoTech.

Dr. Czerwinski received an M.Sc. degree in animal husbandry from the Main School of Rural Economy, Warsaw, Poland, in 1981 and received a Ph.D. in pathology from the University of Maryland at Baltimore, in 1993.  After completing his postdoctoral training in School of Pharmacy at the University of Washington and Fred Hutchinson Cancer Center in Seattle, Dr. Czerwinski joined XenoTech in 1998.  At XenoTech he held positions of Principal Scientist and Director of Cell & Molecular Biology overseeing XenoTech's R&D, Enzyme Induction and Products departments.

Dr. Czerwinski's research focuses on in vitro hepatic functions related to drug safety. At XenoTech, Maciej's heart lies in improving business process through scientifc innovation.

Joanna Barbara , Ph.D.

Joanna Barbara is a Mass Spectrometry Specialist in the Department of Drug Metabolism and Analytical Chemistry. She specializes in metabolite characterization and biotransformation route determination for drugs in development.

Dr. Barbara earned her Ph.D. degree in Analytical Chemistry from the University of Florida in 2007 under the joint direction of Dr. David Powell and Dr. John Eyler. Her research focused on developing techniques in high-resolution mass spectrometry for noncovalent complex analysis. She subsequently joined XenoTech where she is responsible for preclinical metabolism research on drug candidates. Current research interests include the application of accurate mass spectrometry to xenobiotic metabolism studies with a focus on reactive metabolites and metabolism-dependent inhibitors of drug metabolizing enzymes with potential for drug-drug interactions. Her other major area of interest is the development and application of novel analytical technologies, particularly in the area of mass spectrometry, for pharmaceutical research.

 

Andrew Parkinson , Ph.D

Andrew Parkinson is founder and CSO of XenoTech LLC.  He is also adjunct professor of Pharmacology and Toxicology at the University of Kansas Medical Center.

Dr. Parkinson received a B.Sc. degree in medical biochemistry from the University of Surrey, England, in 1977 and received a Ph.D. degree in biological chemistry from the University of Guelph, Canada, in 1981.  After completing his postdoctoral training in drug metabolism at Hoffmann-La Roche, Dr. Parkinson joined the faculty at the University of Kansas Medical Center where he was Professor of Pharmacology and Toxicology and Associate Director of the Center of Environmental and Occupational Health until June 30, 1999.  He founded XenoTech LLC in 1994.

Dr. Parkinson is a member of the editorial board of several scientific journals and is an active member of several scientific societies.  He has served on NIH study section and is a consultant to several pharmaceutical companies and the FDA. Dr. Parkinson’s research focuses mainly on hepatic drug metabolism and toxicity, with a special emphasis on cytochrome P450 and human-based in vitro systems.